Data gathered: May 27
AI Stock Analysis - Iovance Biotherapeutics (IOVA)
Analysis generated May 24, 2025. Powered by Chat GPT.
Iovance Biotherapeutics, Inc. is a biotechnology company focused on developing cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs). Their innovative approach aims to harness and enhance the power of the body's immune system to attack cancer cells, positioning them as a potentially transformative player in the oncology field. The recent developments and approvals in their clinical trials have been pivotal in driving investor interest and stock performance.
Stock Alerts - Iovance Biotherapeutics (IOVA)
 |
Iovance Biotherapeutics | May 25 AI Score is up by 30% in the last couple of days. |
|
Iovance Biotherapeutics | May 21 Price is down by -8.6% in the last 24h. |
|
Iovance Biotherapeutics | May 20 News Alert: IOVA CLASS ACTION NOTICE: Iovance Biotherapeutics, Inc. has been Sued for Securities Fraud after 44% Stock Drop – Contact BFA Law if You Suffered Losses (NASDAQ:IOVA) |
|
Iovance Biotherapeutics | May 20 Employee Rating is up by 6.7% over the last month. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Iovance Biotherapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 44 | Sign up | Sign up | Sign up |
| Sentiment | 92 | Sign up | Sign up | Sign up |
| Webpage traffic | 24,000 | Sign up | Sign up | Sign up |
| Employee Rating | 64 | Sign up | Sign up | Sign up |
| Google Trends | 39 | Sign up | Sign up | Sign up |
| Patents | 191 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 456 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 16,123 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,703 | Sign up | Sign up | Sign up |
| Twitter Mentions | 23 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 52 | Sign up | Sign up | Sign up |
| Linkedin Employees | 898 | Sign up | Sign up | Sign up |
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.
| Price | $1.72 |
| Target Price | Sign up |
| Volume | 5,300,000 |
| Market Cap | $594M |
| Year Range | $1.66 - $12.28 |
| Dividend Yield | 0% |
| Analyst Rating | 90% buy |
| Industry | Biotechnology |
In the news
Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVAMay 26 - Finnhub |
|
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVAMay 25 - Finnhub |
|
IOVA FRAUD: Suffer Losses on Iovance Biotherapeutics, Inc.? You may have been Affected by Fraud and are Urged to Contact BFA Law (NASDAQ:IOVA)May 25 - GlobeNewswire |
|
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVAMay 24 - GlobeNewswire |
|
Kaplan Fox Alerts Investors of Iovance Biotherapeutics, Inc. (IOVA) to the Lead Plaintiff Deadline on July 14, 2025May 23 - Finnhub |
|
Scott+Scott Attorneys at Law LLP Reminds Investors of the Ongoing Action Against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)May 23 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 49M | 50M | -420,000 | -116M | 0 | 0.000 |
| Q4 '24 | 74M | 46M | 28M | -79M | -75M | -0.260 |
| Q3 '24 | 59M | 40M | 19M | -84M | -89M | -0.280 |
| Q2 '24 | 31M | 37M | -5.6M | -97M | -91M | -0.340 |
| Q1 '24 | 720,000 | 13M | -12M | -113M | -108M | -0.420 |
Insider Transactions View All
| Vogt Frederick G filed to buy 374,646 shares at $1.7. May 16 '25 |
| Maynard Ryan D filed to sell 7,500 shares at $10.1. November 14 '24 |
| Dukes Iain D. filed to buy 54,000 shares at $9.2. February 20 '24 |
| MCPEAK MERRILL A filed to buy 320,150 shares at $9.2. February 20 '24 |
| Rothbaum Wayne P. filed to buy 28,067,333 shares at $9.2. February 20 '24 |
Similar companies
Read more about Iovance Biotherapeutics (IOVA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Iovance Biotherapeutics?
The Market Cap of Iovance Biotherapeutics is $594M.
What is the current stock price of Iovance Biotherapeutics?
Currently, the price of one share of Iovance Biotherapeutics stock is $1.72.
How can I analyze the IOVA stock price chart for investment decisions?
The IOVA stock price chart above provides a comprehensive visual representation of Iovance Biotherapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Iovance Biotherapeutics shares. Our platform offers an up-to-date IOVA stock price chart, along with technical data analysis and alternative data insights.
Does IOVA offer dividends to its shareholders?
As of our latest update, Iovance Biotherapeutics (IOVA) does not offer dividends to its shareholders. Investors interested in Iovance Biotherapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Iovance Biotherapeutics?
Some of the similar stocks of Iovance Biotherapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.